SonoThera

Executive Summary

SonoThera is a preclinical biotechnology company developing a non-invasive, ultrasound-mediated delivery (UMD) platform for genetic medicines. Unlike viral vectors, which are limited by immunogenicity, payload size constraints, and manufacturing complexity, SonoThera's UMD technology uses focused ultrasound to transiently permeabilize cell membranes, enabling organ-specific delivery of diverse nucleic acid payloads—including plasmid DNA, mRNA, siRNA, and gene editing components—without size restrictions. The platform is designed to be redosable, well-tolerated, and cost-effective, potentially addressing key bottlenecks in gene therapy. SonoThera aims to unlock the full potential of genetic medicine by enabling targeted delivery to tissues such as liver, muscle, and tumors, with initial focus on rare monogenic diseases and oncology. The company is currently in the preclinical stage, advancing its lead programs toward IND-enabling studies. While no financial details or valuation are publicly available, the technology has attracted interest due to its potential to overcome limitations of existing delivery methods. However, significant development and regulatory hurdles remain before clinical validation.

Upcoming Catalysts (preview)

• TBDIND filing for lead program in a rare monogenic disease25% success
• Q4 2026Presentation of in vivo efficacy data in a preclinical model70% success
• TBDStrategic partnership with a large pharma for platform development30% success